VivoSeq
Other

Memory

142

Pipeline Programs↗

25

Active Trials↗

55

Companies Involved↗

Memory is a highly competitive landscape with 142 programs across 55 companies. The most active players are AstraZeneca, Biogen, Eastern Cooperative Oncology Group. 33 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

30/100

Mech. Concentration

7/100

Completion Rate

84/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

2 programs

Phase 1Biogen logo

Biogen

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 1F

Fresenius Kabi Oncology Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical22

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Risperidone

Wim Janssens

Losartan

Organon and Co

Rapamycin

Maastricht Radiation Oncology

Ketamine Hydrochloride

Boehringer Ingelheim

Phase 129

Resveratrol

National Cancer Institute (NCI)

Melphalan

Apotex Inc.

Filgrastim

Eastern Cooperative Oncology Group

Fentanyl

Cephalon

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 243

Sirolimus

Prism Pharmaceuticals

Cyclophosphamide

Baxter Healthcare Corporation

Rituximab

Roche

Cannabidiol

Jazz Pharmaceuticals

NT-020

University of South Florida

Phase 315

Caffeine

Hikma Pharmaceuticals LLC

Escitalopram

AbbVie

Tritanrix™-Hepb

GSK

Hiberix™

GSK

Pneumococcal Vaccine

GSK

Approved33

Galantamine

Wim Janssens

Zolpidem

Purdue Pharma LP

Oxytocin

Retrophin

Propranolol

Wyeth-Lederle Vaccines

Mirabegron

Astellas

Analysis

Modality Breakdown

87%

Small molecule

122 of 140 classified programs — the dominant modality here.

13%ALL OTHERSVaccine86%Monoclonal antibody43%Cell therapy32%Protein / enzyme21%Peptide1<1%

Small molecule leads; the ring shows all 140 classified programs, each share of the total. Modality classified for 100% of 170 pipeline programs.

Analysis

Trial Status

157

clinical trials

Completed94 · 60%
Unknown status20 · 13%
Terminated13 · 8%
Recruiting11 · 7%
Active, not recruiting9 · 6%
Withdrawn5 · 3%
Other5 · 3%

Clinical Trials

Trial Activity

157 trials

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07052370·30 enrolled
Pharmacological Modulation of Brain Oscillations in Memory Processing
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT05594017·60 enrolled
The Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression
Recruiting·UUnity Health Toronto·N/A·NCT06163625·50 enrolled
Glutamate Emotion Memory Study
Recruiting·UUniversity of Oxford·N/A·NCT05809609·60 enrolled
Testosterone-induced Muscle Memory and Underlying Mechanisms
Recruiting·—·N/A·NCT06188767·30 enrolled
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Recruiting·WWashington University School of Medicine·Phase 1/2·NCT06158828·68 enrolled
Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression
Recruiting·UUniversity of Basel·Phase 2·NCT06751784·38 enrolled
Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect on Psychophysiological Reactivity During Traumatic Imagery
Recruiting·MMassachusetts General Hospital·Phase 4·NCT05853627·80 enrolled
H22 - Unconscious Mind Training and Memory Encoding
Recruiting·DDream Video LLC·Preclinical·NCT07597603·100 enrolled
A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Examine Lysoveta on Cognitive Function in Healthy Adults With Self-perceived Memory Problems
Recruiting·AAker BioMarine Human Ingredients AS·Preclinical·NCT07034794·138 enrolled
Cannabis and Memory
Recruiting·—·N/A·NCT07679581·64 enrolled
Cannabinoids, Learning, and Memory
Active, not recruiting·YYale University·Phase 1·NCT02407808·80 enrolled
Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses
Active, not recruiting·—·Phase 4·NCT06824779·30 enrolled
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT02790515·170 enrolled
VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination
Active, not recruiting·UUniversity of Washington·Phase 4·NCT04403139·50 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)